Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
hyperphosphatemia/niðurgangur
Krækjan er vistuð á klemmuspjaldið
Bls 1 frá 52 niðurstöður
Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
No conventional phosphate binder is entirely satisfactory for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD). Consequently, there is a need for new agents. One such agent is lanthanum carbonate (La). This large-scale study compares the safety of La with
Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND
Hyperphosphatemia is a common problem in patients with end-stage renal disease (ESRD) who are on maintenance hemodialysis (HD) and contributes to the development of secondary hyperparathyroidism and cardiovascular complications. Nicotinamide (NAM) has been shown in some studies to inhibit
Herbal and dietary supplements related to diarrhea and acute kidney injury: a case report.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Background There is very little evidence relating to the association of herbal medicine with diarrhea and the development of acute kidney injury (AKI). This study reports a case of diarrhea-induced AKI, possibly related to an individual ingesting copious amounts of homemade mixed fruit and herb
The acidosis of cholera. Contributions of hyperproteinemia, lactic acidemia, and hyperphosphatemia to an increased serum anion gap.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
To study the metabolic acidosis that occurs during the diarrhea of cholera, we examined the serum anion gap in 21 patients with hypovolemic shock due to Vibrio cholerae infection. Measurements of serum electrolytes, as well as divalent cations and the anionic contributions of serum proteins,
[Effect of Rhubarb Combined Medicinal Activated Carbon on Levels of Serum Phosphorus, Calci- um-Phosphorus Product, and Parathyroid Hormone in Hemodialysis Patients with Hyperphosphatemia].
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Objective To study the effect of rhubarb combined medicinal activated carbon on levels of serum phosphorus and calcium-phosphorus product, as well as parathyroid hormone in hemodi- alysis patients with hyperphosphatemia. Methods Totally 126 hemodialysis patients with hyperphos- phatemia who had
Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Bixalomer (Bix) is an amine-functional polymer, non-calcium-containing phosphate (P) binder, and has been clinically available in Japan recently. Bix is expected to cause fewer gastrointestinal (GI) side-effects as compared with sevelamer hydrochloride (SH), because of less expansion of Bix in the
Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The objective of this article was to assess the safety and efficacy of long-term administration of PA21.
Phase III, open-label, long-term study in 15 sites in Japan.
Japanese hemodialysis patients (N = 161) with hyperphosphatemia aged ≥20 years undergoing stable maintenance hemodialysis 3 times
PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
Limitations of conventional phosphate binders have led to the development of novel non-calcium, non-aluminium agents for use in patients with chronic kidney disease (CKD). The iron-based agent PA21 (stabilized polynuclear iron(III)-oxyhydroxide) has high phosphate binding capacity in
JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
JTT-751 (ferric citrate hydrate) is a novel iron-based phosphate approved in Japan for the treatment of hyperphosphatemia in dialysis and nondialysis patients with chronic kidney disease.
METHODS
In this phase 3, multicenter, open-label, dose-adjusted study, we investigated the efficacy
Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Control of phosphorus accumulation in chronic renal insufficiency is crucial to the prevention of secondary hyperparathyroidism and metastatic calcification. In early renal failure, calcitriol levels are normal and parathyroid hormone levels are elevated. The phosphorus levels are maintained in the
[Pharmacological, pharmaceutical and clinical profiles of sucroferric oxyhydroxide (P-TOL® Chewable Tab. 250 mg, 500 mg), a therapeutic agent for hyperphosphatemia].
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Sucroferric oxyhydroxide (P-TOL® chewable tablets, 250 and 500 mg) is a phosphate binder for oral use; it is composed of polynuclear iron (III)-oxyhydroxide, sucrose, and starches, and is currently indicated for alleviating hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
Nicotinic acid and related compounds: A meta-analysis of their use for hyperphosphatemia in dialysis patients.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND
Studies indicate that nicotinic acid and related compounds may decrease phosphorus concentrations effectively by reducing the absorption in the gastrointestinal tract. However, the efficacy and safety of oral niacin treatments have only been investigated in a limited number of small-scale
Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND
Hyperphosphatemia is common in chronic kidney disease (CKD) and associated with mortality and morbidity. We aimed to evaluate the dose-dependent efficacy and safety of PA21 (sucroferric oxyhydroxide), an iron-based phosphate binder, in Japanese hemodialysis patients with
Quantitative physicochemical analysis of acid-base balance and clinical utility of anion gap and strong ion gap in 806 neonatal calves with diarrhea.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND
Acid-base abnormalities in neonatal diarrheic calves can be assessed by using the Henderson-Hasselbalch equation or the simplified strong ion approach which use the anion gap (AG) or the strong ion gap (SIG) to quantify the concentration of unmeasured strong anions such as
What's new in clinical pharmacology and therapeutics.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The US Food and Drug Administration (FDA) has approved several new drugs in the last few years. We have summarized a few of these that should be of interest to a primary care physician. These belong to either a new class of drugs or have a better drug profile in terms of ease of administration,
Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum
- Virkar á 55 tungumálum
- Jurtalækningar studdir af vísindum
- Jurtaviðurkenning eftir ímynd
- Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
- Lestu vísindarit sem tengjast leit þinni
- Leitaðu að lækningajurtum eftir áhrifum þeirra
- Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum
Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum
